This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: Mereo Biopharma 1 Limited. Active years: 2020-2021.
Company Filing History:
Years Active: 2020-2021
Title: Colin Orford: Innovator in Pharmaceutical Dosage Regimens
Introduction
Colin Orford is a notable inventor based in London, GB, recognized for his contributions to the field of pharmaceuticals. He holds three patents that focus on innovative dosage regimens aimed at treating various medical conditions. His work is significant in advancing treatment options for patients suffering from chronic illnesses.
Latest Patents
Colin Orford's latest patents include a novel dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). This invention involves the administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof. Additionally, he has developed a dosage regimen for the treatment of acute exacerbations of inflammatory conditions, utilizing the same compound to improve patient outcomes.
Career Highlights
Colin Orford is currently associated with Mereo Biopharma 1 Limited, where he continues to innovate in the pharmaceutical sector. His work is pivotal in developing effective treatment strategies that address urgent medical needs.
Collaborations
Colin collaborates with esteemed colleagues such as Cyril Clarke and Colm Farrell, contributing to a dynamic team focused on advancing healthcare solutions.
Conclusion
Colin Orford's innovative work in pharmaceutical dosage regimens exemplifies his commitment to improving patient care through scientific advancements. His contributions are vital in the ongoing battle against chronic diseases.